XTalks

JANUARY 2, 2024

For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. Vyjuvek is a gene therapy that employs a herpes simplex virus type 1 (HSV-1) vector. Upon Vyjuvek’s entry into cells, the vector genome is integrated into the nucleus, initiating the transcription of the encoded human COL7A1.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. Quantum Genomics launched its Phase III REFRESH trial in difficult-to-treat or resistant hypertension. It is being administered together with FOLFOX chemotherapy. BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Immune-Mediated Encephalitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Immune-Mediated Encephalitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52